Abstract 302P
Background
DNA repair pathways are implicated both in carcinogenesis and progression of cancer. The genetically determined baseline expression level of DNA repair genes is associated with risk of cervical pre-cancer and cancer. In this study, we aim to evaluate expression level of one such DNA repair gene -Excision Repair Cross- Complementation Group 4 (ERCC4) and its correlation to various clinical and pathological parameters in cervical cancer in North Indian population.
Methods
Expression profiling of ERCC4 in 55 histopathologically confirmed cervical tumor biopsies and 25 control samples (hysterectomy) were done using Real time PCR(q-PCR), western blot analysis. Correlation analysis was done with different clinical and pathological parameters. ROC curve assessment was done to check the diagnostic utilities of the calculated data. One way ANOVA and t-test were used to calculate statistical significance using Graphpad PRISM 9.
Results
Relative fold change for mRNA expression analysis showed up-regulation of ERCC4 in 78.2% (n=43) patient biopsies, calculated by ΔΔct method. At translational level, the up regulation was around 52% (n=28). The up-regulations were significant with p value less than 0.05. Also, ERCC4, mRNA expression showed positive correlation with tumor stage and grade. Positive correlation was also observed in ERCC4 protein expression with respect to different age groups and histological status. High risk HPV-18 strain type was shown to be more influential in up regulating ERCC4 expression, both at transcriptional and translational level.
Conclusions
ERCC4 is significantly up-regulated at both transcriptional and translational levels in cervical cancer patient cohort, comprising of North Indian population. Higher expression of ERCC4 in tumor samples suggests its role as a potential diagnostic and/or prognostic marker in Ca Cervix.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Medical Sciences, BHU, Varanasi, India.
Funding
BHU under Institute of Eminence (IoE).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract